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Abstract
Purpose The purpose of this studywas to evaluate themeasure-
ment of heart rate undertaken in clinical studies by (1) assessing
the repeatability and reproducibility of heart rate measurements
by various methods and under various conditions and (2) deter-
mining whether a single heart rate measurement at rest is repre-
sentative of the circadian and inter-day variation of heart rate.
Methods Prospective cohort study in 102 patients with vari-
ous types of heart disease at Duisburg Heart Center, Germany
between 2011 and 2012. The heart rate measurements were
based on self-assessment, ECG tracings at rest, and bicycle
stress ECG in the office as well as 24-h Holter ECG.
Results Office measurements and self-assessment at rest as
well as 24-h Holter ECG and self-assessment at rest are highly
correlated, but no correlation between self-assessment and
office recordings/24 h recordings under exercise conditions
was seen. Coefficient of variability was below 10 % for the
self-assessment and for office measurements at rest. There
were no differences in coefficient of variability during the
day and within the 6 days for self-assessment of heart rate at
rest and circadian variation was normal.
Conclusions At rest heart rate measurements by various
methods agree sufficiently and inter-day/circadian variation
is adequately represented. Under exercise conditions self-
assessment of heart rate is not valuable and use of 24 h
Holter as well as stress ECG recordings is necessary. Thus,
self-reported heart rate measurements by the patient at rest
seem to be reliable, but should be used in clinical studies only
for heart rate assessment at rest.
Keywords Heart rate variability . Heart rate measurement .
Pharmacological intervention studies . Clinical studies . Heart
disease
Introduction
Previous epidemiological studies generated evidence for a cor-
relation between heart rate and risk of cardiovascular disease and
hence life expectancy in the general population and in patients
with coronary heart disease (CHD) [1–4]. Most of coronary
perfusion takes place in diastole, a phase characterized by a
reduced wall tension compared to systole. Prolonging diastole
should improve coronary perfusion and might thus decrease
CHD morbidity and mortality [5]. Accordingly, several studies
have addressed the effect of heart rate lowering drugs on symp-
toms and prognosis of patients with heart failure andCHD [6, 7].
In these studies, dose titration of heart rate lowering agents
was primarily based on measurements of heart rate in ECG
tracings at rest, occasionally on 24-h Holter recordings as
well. Some studies simply relied on pulse counts obtained
by the patients.
The setting for the ECG recording was not specifically
defined or described in the study protocols or other publica-
tions [8]. Furthermore, a correlation of ECG derived parame-
ters with Breal world^ measurements of heart rate by the pa-
tient during his daily activities has never been performed.
There is also some uncertainty on the variability of heart rate
measurements within the day and from day to day. Finally,
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with respect to pathophysiology, the question arises how well a
single heart rate measurement at rest reflects the heart rate pat-
tern during the whole day. The lack of information on all these
issues sheds some doubt on the significance of single resting
heart rate measurements suggested by respective studies.
We therefore analyzed heart rate measurements obtained
with various methods and at various points in time. Our pri-
mary objectives were (1) to assess the repeatability and repro-
ducibility of heart rate measurements by various methods and
under various conditions and (2) to determine whether a sin-
gle, casual heart rate measurement at rest is representative of
the heart rate pattern during the day and between six consec-
utive days. Furthermore, data collected might shed light on the
issue, whether self-reported heart rate measurements by the
patient are reliable and, therefore, can be used for heart rate
assessment in clinical studies.
Methods
Study patients and data collection
This investigation was a single center, prospective cohort study
in 102 patients aged 42–80 years with various types of heart
disease treated according to ESC and National Guidelines [9,
10]. Patient screening was done in the hospital and data sam-
pling was continued upon discharge from the hospital.
Independent of the underlying heart disease, eligible patients
had an indication for heart rate lowering therapy (CAD and
heart failure) and received all drugs according to standard rec-
ommendations. The focus was, however, not on specific ther-
apies, but on the assessment of heart rate under various condi-
tions. Heart rate was determined according to protocol by the
patient himself, and by study personnel blinded for the patient
measurements, based on resting ECGs, Holter recordings, and
exercise test ECG tracings. For the complete protocol, please
refer to the online-publication.
Definitions
Variability in heart rate during the day and day to day variabil-
ity were analyzed and compared to the heart rate recorded by
the ECG at rest in the clinic (office) based on coefficient of
variability, repeatability, and reproducibility. Change and re-
producibility provide values of the upper limits for the varia-
tion with high probability (that is for the difference between
repeated measurements). In order to compare self-assessments
and the heart rate recorded by the ECG at rest in the clinic,
Holter recordings and stress ECG, heart rates agreement was
used and defined as a deviation of less than 10 beats/min from
mean. For the visual analysis of the 24-h heart rate pattern, we
defined a tachycardia period as the duration in time of heart
rates deviation of more than 10 beats/min from mean.
Data analysis
Measurements recorded during the ambulatory period were
stored on a personal computer and screened for artifacts as
defined by previously described criteria [11]. Only recordings
with less than 20 % error measurements were accepted for
evaluation. Regarding self-assessment, only daytime values
were available.
Statistical analysis
Categorical variables are described by using percentages and
absolute numbers, continuous variables by using mean, stan-
dard deviation, and range. The Brevais-Pearson coefficient
was used for correlations, and reproducibility was assessed
using the Bland-Altman approach [12]. Change between du-
plicate recordings was calculated by subtracting the first from
the second recording. A comparison between baseline and
repeat recording was done by using the t test. Consistency
was obtained by calculating the difference between baseline
and repeat recordings, disregarding the sign of the difference.
Repeatability was defined as twice the standard deviation
of the changes between two repeated recordings. To compare
the reproducibility of different variables, the maximal biolog-
ical variation (MBV) of the variables was calculated (twice the
standard deviation of the between-measurement differences,
divided by four times the standard deviation of the two dupli-
cate recordings) [13]. All statistical calculation was performed
using SAS 9.3.
Results
Clinical and treatment characteristics
The clinical characteristics of the patient population are shown
in Table 1. The proportion of patients with hyperlipidemia,
hypertension, smoking habits, peripheral arterial obstructive
disease, or diabetes mellitus reflected a typical population
with heart disease. Almost all were on heart rate lowering
medication and most of them had only a slight reduction in
ejection fraction. Most performed moderate physical activity
in terms of exercise intensity defined by the MET concept at
some point of the day. Nearly half of the patients exposed
themselves to heavy physical activity striving for cardiovas-
cular fitness and the heart frequency range observed in this
study is therefore comparable to that one of a normal, healthy
population of the same age range. Exercise levels of peak
physical activities at home and during bicycle stress ECG test
expressed in METwere comparable in 72 % of patients (data
not shown).
According to the protocol, we expected the patients to re-
cord six measurements at rest during the day for a total of
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6 days and three measurements per day under exercise condi-
tions. For consistency reasons, we used only self-
measurement of heart rate with corresponding Holter record-
ings and office treadmill heart rate measurements for statistical
analyses. Therefore, the number of observations read for the
analysis of heart at rest assessed by self-assessment was 3559
in total and 3474 were used. Similarly, for the comparison of
heart rate under exercise conditions assessed by self-assess-
ment, the number of observations read was 1831 in total and
1620 were used. Heart rates measured under various condi-
tions are reported in Table 2. Mean heart rate at rest was below
70 beats/min. As expected, standard deviations of the mean
heart rate were higher under exercise conditions. Correlation
coefficients between office measurements and self-assessment
at rest as well as 24-h Holter ECG and self-assessment at rest
are shown in Table 3. Correlation coefficients between office
measurements and self-assessment at rest as well as 24-h
Holter ECG and self-assessment at rest were similar and much
higher than any correlation under exercise conditions. In fact,
looking at the correlation coefficients for exercise measure-
ments, there was only a very weak association between office
measurements and those based on self-assessment.
Change, consistency, repeatability, mean biological vari-
ability (MBV), and coefficient of variability for heart rate
Table 1 Base line characteristics of patients included in study
Demographics
Total, % 100 (102)
Female, % 29.4 (30/102)
Age, (years) mean(±SD): 63.2 (±10.43)
Age < 50, % 10.8 (11/102)
Age 50–70, % 60.8 (62/102)
Age > 70, % 28.4 (29/102)
Clinical presentation
BMI, kg/m2 mean (±SD): 27.5 (±3.6)
BMI > 30, % 19.6 (20/102)
Medical history❋
Coronary heart disease, % 75.2 (76/101)
Hypertension, % 91.1 (91/101)
Hypercholesterolemia, % 54.5 (55/101)
Diabetes mellitus, % 12.9 (13/101)
AF, % 14.9 (15/101)
Ejection fraction
Slight reduction (EF 40–60 %), % 27.7 (28/101)
Moderate reduction (EF 30–40 %), % 8.9 (9/101)
Severe reduction (EF < 30 %), % 3.9 (4/101)
Contraindication to ß-Blockade, % 6.9 (7/101)
Medication❋
Heart rate lowering agents, % 99.0 (101/102)
Diuretics, % 54.9 (56/102)
Antihypertensive medication, % 77.5 (79/102)
Statins, % 75.5 (77/102)
Inhibition of platelet function and anticoagulation,% 95.1 (97/102)
Thyroid hormones 8.8(9/102)
Classification of physical activity in terms of exercise intensity❋
Light, % 77.5 (79/102)
Moderate, % 92.2 (94/102)
Heavy, % 47.1 (48/102)
Very heavy, % 20.6 (21/102)
Unduly heavy, % 3.9 (4/102)
BMI body mass index, SD standard deviation, AF atrial fibrillation, EF
ejection fraction
❋Multiple entries possible
Table 2 Mean (SD), minimum, and maximum values of heart rates
measured under various conditions
Period Mean SD Range
HR office at resta 67.4 10.1 45–98
HR office treadmill maximum 118.6 19.2 68–164
HR 24 h all valuesb 69.5 8.7 47–95
HR 24 h minimum 51.5 8.3 35–93
HR 24 h maximum 113.5 17.9 80–172
HR self all valuesc 66.6 9.8 48–105
HR self minimum 57.0 11.1 46–96
HR self maximum 88.6 16.1 60–146
HR heart rate, HR office at rest HR derived ECG recordings at rest in the
clinic, HR 24 h HR derived from 24-h Holter recording, HR self HR
derived from self-assessment; HR office treadmill HR derived from a
bicycle ECG stress tests, SD standard deviation expressed as beats/min
aMean of 3 ECG recordings at rest
b Recorded mean of 24-h Holter recording
cMean of all values measured by patients
Table 3 Mean values (±SD) and correlation coefficients (CC) between
values of heart rate measured under various conditions in the whole study
population
Period Mean values (±SD) CC
HR office at rest 67.4 10.1 0.68
HR self all values 66.6 9.8
HR office treadmill maximum 118.6 19.2 0.17
HR self maximum 88.6 16.1
HR 24 h all values 69.5 8.7 0.67
HR self all values 66.6 9.8
HR 24 h minimum 51.5 8.3 0.57
HR self minimum 57.0 11.1
HR 24 h maximum 113.5 17.9 0.26
HR self maximum 88.6 16.1
HR heart rate, HR office at rest HR derived ECG recordings at rest in the
clinic, HR 24 h HR derived from 24-h Holter recording, HR self HR
derived from self-assessment, HR office treadmill HR derived from a
bicycle ECG stress tests
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measured at rest in the office and with self-assessment are
reported in Table 4. Consistency and coefficient of variability
indicated a greater variation for office measurements at rest
than for self-assessment. For all measurements, the coefficient
of variability was below the acceptable value of 10 % and
reproducibility was modest. Within self-assessment data, the
change was very small but as would have been expected the
MBV was higher. Repeatability was worse for the heart rate
variability within a day as well as for the heart rate variability
within different days during the 12 o‘clock self-assessment at
rest. Looking at heart variability of the self-assessment at rest
during the day, there were no differences in coefficient of
variability during the day (HR self all day) and within the
6 days of self-assessment analyzing the different time points
of measurement except for the midday measurement.
Analyzing repeatability indices in subgroups of patients with
reduced ejection fraction or with different intensities of phys-
ical exercise, these indexes were worse, but with no relevant
differences in repeatability (data not shown).
Due to the study design (only one 24-h Holter recording was
performed), we used heart rates agreement defined as a devia-
tion of less than 10 beats/min from mean in order to compare
heart rates under the various conditions. Maximum heart rates in
Holter recordings during daytime will correspond to exercise in
a patient under adequate heart rate controlling medication and
minimum heart rate will correspond to rest (Table 2). Therefore,
it was possible to compare heart rates under exercise (office
stress ECG and Holter recordings) and at rest (ECG at rest in
the clinic and Holter recordings) to heart rates of self-assessment
(Table 5). Comparing heart rates of office stress ECG vs. heart
rates of self-assessment under exercise conditions, only 10 % of
the measurements showed an agreement with heart rate deter-
mined by self-assessment. The same holds true for the compar-
ison of maximum heart rates documented by the Holter record-
ing during the daytime with heart rates of self-assessment under
exercise. In this case, only 9 % of patients showed comparable
heart rates to the self-assessment. Comparison of the mean heart
rate during the Holter recording with the mean heart rate of the
self-assessment showed a better agreement with 80 % of the
measurements being comparable to the heart rate determined
by self-assessment. Similar results were obtained comparing
the minimum heart rate of the Holter recording with the
minimum heart rate of the self-assessment with 76 % of the
measurements showing an agreement.
Analyzing the 24-h heart rate pattern for tachycardia pe-
riods, we observed the following:
1) 60 % of patients showed tachycardia periods with a du-
ration of less than 25 % of the time recorded (range 0–
24.3 %, mean 15.9 %) during the 24 h,
2) 38 % of patients presented tachycardia periods with a
duration of 25 to 50 % of the time recorded (range
25.3–44.6 %, mean 32.1 %) during the 24 h and,
3) only 2 % of patients had tachycardia periods with a dura-
tion of 50–75% of the time recorded (range 57.6–63.6 %,
mean 60.6 %) during the 24 h. During the sleeping hours,
the registered tachycardia periods encompassed 12.4% of
the time recorded (range 0–52.2 %).
The study included 15 patients with atrial fibrillation. All of
them were already diagnosed with atrial fibrillation and no
newly diagnosed atrial fibrillation was detected. Twenty per-
cent (3/15) presented with permanent fibrillation and 80 %
(12/15) with paroxysmal fibrillation. In the patients with par-
oxysmal fibrillation, 9/12 patients showed sinus rhythm, 2/12
patients had permanent fibrillation, and 1/12 patients showed
only short phases of atrial fibrillation on 24-h Holter record-
ings. Analyzing the 24-h heart rate pattern for tachycardia
periods, we observed the following: (1) 7/15 patients showed
Table 4 Reproducibility indexes
for heart rate measured at rest in
the office and with self-
assessment by patients
Period Change p value Consistency Repeatability MBV (%) CV
HR office at rest −2.31 0.0046 7.6 14.5 59 9.3
HR self all values −0.06 0.4777 5.9 15.1 66 7.4
HR self morning values −0.09 0.2956 5.5 14.5 72 7.6
HR self midday values −0.07 0.5296 5.8 16.0 73 8.1
HR self night values −0.09 0.0499 5.3 13.1 71 7.5
HR heart rate, HR office at rest HR derived ECG recordings at rest in the clinic, HR self HR derived from self-
assessment, MBV mean biological variability, CV coefficient of variability
Table 5 Agreement between self-assessment and Holter recordings
and office treadmill heart rate measurements
Patients with HR comparable
to self-assessment
HR office treadmill max 10 %
HR 24 h mean 80 %
HR 24 h min 76 %
HR 24 h max 9 %
Proportion (%) of patients showing comparable heart rates with the self-
assessment are depicted
HR heart rate, HR office treadmill HR derived from a bicycle ECG stress
tests, HR 24 h HR derived from 24-h Holter recording, HR self HR
derived from self-assessment
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tachycardia periods with a duration of less than 25 % of the
time recorded (range 7.5–23.6 %, mean 15.5 %) during the
24 h, (2) 7/15 patients presented tachycardia periods with a
duration of 25 to 50 % of the time recorded (range 27.2–
37.0 %, mean 34.8 %) during the 24 h, and (3) only 1/15
patients had tachycardia periods with a duration of 50–75 %
of the time recorded (range 56.7 %) during the 24 h. In the
subgroup of the three patients with permanent atrial fibrilla-
tion 2/3 patients showed tachycardia periods with a duration
of less than 25 % of the time recorded and 1/3 patients tachy-
cardia periods with a duration of 25 to 50 % of the time
recorded. In the subgroup of patients with paroxysmal atrial
fibrillation, 6/12 patients showed tachycardia periods with a
duration of less than 25 % of the time recorded and 5/12
patients tachycardia periods with a duration of 25 to 50 % of
the time recorded and 1/12 patients had tachycardia periods
with a duration of 50–75 % of the time recorded.
Discussion
Key findings
We hypothesized that the measurement of heart rate undertak-
en in clinical studies was not representative of (1) the circadian
and inter-day variation and (2) of the exercise-induced varia-
tion of heart rate during the patient’s everyday life.
Our hypothesis was only partially confirmed and we could
show that the exercise-induced variation of heart rate during
the patient’s everyday life is not adequately represented in
clinical studies. Instead self-reported heart rate measurements
at rest represent adequately the inter-day and circadian varia-
tion of heart rate. Self-reported heart rate measurements by the
patient at rest are thus reliable, but can be used in clinical
studies only for heart rate assessment at rest.
Study strength and limitations
Major part of this study is a measurement method comparison.
The statistical aspects of measurement method comparisons
have been thoroughly discussed by Altman and Bland [12,
14]. According to their findings, the comparison of mean
values by significance testing is inappropriate because a non-
significant result might occur as result of both a large mea-
surement error and agreement on the average. The calculation
of the correlation coefficient is another often misused method
because it is not a measure of agreement, but of association.
For this reason, we used the coefficient of variability that has
the advantage of indicating the relation between the magni-
tude of observations and their variations. In addition, the use
of the coefficient of variation allows for comparison between
different methods and different groups of subjects.
Next, defining what is the normal resting heart rate and
what is an acceptable deviation is troublesome. We based
our decision on the following studies. First, in a study on
resting heart rate in Diabetics with altered autonomic function,
a standard deviation (SD) of to 10 beats/min was noticed in the
healthy comparison group [15]. In a much larger study by
Erikssen and Rodahl in 2014 apparently healthy middle-
aged men aged 40–59 years, the mean heart rate at rest was
61 beats/min and the observed SD was 9.7 beats/min [16]. In
this study, self-assessment was compared to auscultation and
resting ECGs. In another publication by Palatini et al. [11] on
the reproducibility of heart rate measurement in the clinic and
with 24 h intermittent recorders, a SD of up to 9.6 beats/min
was accepted. In one of the larger pharmacological interven-
tion studies—the BEAUTIFUL study—a SD of 8.7 beats/min
from mean was reported [5, 7]. Based on these studies, we
considered a deviation of more than 10 beats/min from mean
to be relevant.
Another limit of this study is the relatively small number of
patients included in the study, but this is counterbalanced by
the high number of observations used. Furthermore, we did
not have a normal control group. However, this is not inter-
fering with the objective of this study focused on the evalua-
tion of heart rate measurement undertaken in clinical studies.
Comparison with other studies and interpretation
of results
As to our knowledge, there are no published studies on this
argument and therefore comparison with the results of others
may be only indirect and limited.
In healthy individuals, there is a circadian pattern of heart
rate with a peak heart rate around 10 am, and a gradual decline
during the night with a nadir just prior to awakening [17].
Disease states such as congestive heart failure with alterations
in autonomic tone and medications can have an effect on
circadian rhythms [18]. The healthy controls in two studies
on abnormalities in ambulatory 24 h heart rate in diabetes and
in inappropriate sinus tachycardia showed tachycardia periods
spanning 29 and 42 % of the registered 24 h, respectively. No
tachycardia periods occurred during the sleeping hours [19,
20]. This heart rate pattern was not changed in our population
on heart rate lowering therapy except for the presence of
tachycardia periods during the sleeping hours. Furthermore,
there were no differences in coefficient of variability during
the day and within the 6 days for self-assessment of heart rate
at rest. Due to the low numbers and missing follow-up evalu-
ation of a possible prognostic, significance of these tachycar-
dia periods during the night is not possible. In addition, self-
assessment with acquisition of about 36 values per patients as
a method of measurement is only slightly superior to three
ECG recordings at rest in evaluating resting heart rate. It is
noteworthy that the coefficients of variability of both methods
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are with a value of less than 10 % in an acceptable range. This
confirms previous data that heart rate recorded over the 24 h
has a better reproducibility than office heart rate and may thus
be a better prognostic indicator than traditional measurement
of resting heart rate in the hospital setting [11]. A possible
reason for the higher statistical correlations in this study with
respect to other studies comprising healthy subjects maybe the
use of heart rate controlling medication [11].
Furthermore, atrial fibrillation might have an impact on the
reproducibility of the various heart rate measurements.
According to our results, atrial fibrillation was not a confound-
ing factor due to fact that most patients in this study had only
paroxysmal fibrillation with a majority of patients still show-
ing sinus rhythm. In addition, analysis of the 24-h heart rate
pattern for tachycardia periods showed that the results of pa-
tients with atrial fibrillation were comparable to patients with
sinus rhythm.
With regard to heart rate assessment under exercise or
stress conditions, self-assessment underestimates the maxi-
mum heart rate patients are exposed to. This seems to be
supported by the fact that peak exercise levels at home and
during bicycle stress ECG were similar in a majority of pa-
tients. Thus, from a methodological point of view, bicycle
exercise ECG as well as 24-h Holter recordings are more
precise in documenting the maximum heart rates reached.
Reasons for the above observation might be (1) the time delay
between exercise and self-measurement and (2) the fact that
the patients may simply have omitted the self-assessment in
certain situations.
Our study suggests that there is no pronounced variability
of heart rate measurements taken at various time points neither
during the day or at different days and, therefore, physiolog-
ical variation in heart rate does not seem to be a confounding
factor in the conduction of pharmacological intervention stud-
ies. With regard to the recording of the maximum heart rate
under exercise or stress conditions self-assessment of heart
rate is not a valuable neither a trustworthy method of investi-
gation. Furthermore, heart rates registered point to relevant
tachycardia under exercise or stress conditions. Noticeably
in none of the intervention studies published so far, the max-
imum heart rate on heart rate limiting medication was docu-
mented. Based on the results of this study, we would recom-
mend future studies to address the question, whether the ex-
tent of the heart rate limiting effect under exercise or stress
conditions influences the end points such as cardiovascular
morbidity and mortality.
Conclusions
Dose titration of heart rate lowering agents in pharmacological
intervention studies is actually based mostly on measurements
of heart rate in ECG tracings at rest. In our study, heart rate
measurements at rest in the office and based on self-
assessment are comparable and reproducible. Physiological
variation in heart rate does not seem to be a confounding
factor in the conduction of pharmacological intervention stud-
ies. But under exercise conditions, heart rate measurements
taken in the office and by 24-h Holter monitoring do not agree
in a sufficient manor with measurements based on self-
assessment.
Consequently, self-assessment of heart rate provides the
same information as conventional methods of measurement
at rest. Under exercise conditions, the routine use of 24-h
Holter as well as stress ECG recordings is helpful for a more
complete data acquisition. Therefore, (1) self-reported heart
rate measurements by the patient seem to be reliable only at
rest and, therefore, should be used in clinical studies only for
heart rate assessment at rest and (2) it seems reasonable to
propose a standardized operating procedure for heart rate mea-
surements in clinical studies comprising ECG tracings at rest
during every visit (a minimum of three), three treadmill ECG,
and three 24-h Holter recordings. Such common standardized
operating procedure may enable the scientific community to
compare more easily clinical studies without being limited by
different methodological designs.
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